In this study, we established MM PDCs, which together with melanoma cell lines were applied to a functional drug testing platform covering 527 approved and investigational oncologic drugs to identify patient-specific treatment options for patients with BRAF wild-type MM. This evidence concerns the gene BRAF and Miyoshi myopathy.